Calcium
Calcium taken near oral ibandronate can markedly reduce absorption and treatment efficacy.
Recommendation: Take calcium later in the day, at least 60 minutes after ibandronate and preferably with a meal.
Prescription ·Strong evidence ·Reviewed May 2026
Ibandronate is a bisphosphonate used for treatment and prevention of postmenopausal osteoporosis. Oral absorption is extremely low and is substantially reduced by food, beverages other than plain water, calcium, magnesium, iron, antacids, and vitamins, so strict fasting administration and mineral separation are essential.
The bottom line
Evidence rating strong. Most-documented uses: treatment of postmenopausal osteoporosis, prevention of postmenopausal osteoporosis, increased bone mineral density. 3 sources indexed (2004–2026), with 5 interaction records on file.
Core mechanism
Ibandronate binds hydroxyapatite at bone resorption surfaces and is taken up by osteoclasts during bone breakdown. As a nitrogen-containing bisphosphonate, it inhibits farnesyl pyrophosphate synthase in the mevalonate pathway, impairing osteoclast function and survival. Reduced osteoclast-mediated resorption increases bone mineral density and lowers vertebral fracture risk.1,3
Take oral ibandronate after an overnight fast with 6 to 8 ounces of plain water only. Remain upright and avoid food, beverages, supplements, and other medications for at least 60 minutes.
Calcium taken near oral ibandronate can markedly reduce absorption and treatment efficacy.
Recommendation: Take calcium later in the day, at least 60 minutes after ibandronate and preferably with a meal.
Magnesium can bind oral ibandronate and reduce its already very low bioavailability.
Recommendation: Avoid magnesium before and for at least 60 minutes after ibandronate; later-day dosing is preferred.
Iron supplements can chelate ibandronate and reduce absorption.
Recommendation: Take iron at a different time of day, not during the fasting ibandronate window.
Zinc may bind oral ibandronate and reduce absorption if taken too close.
Recommendation: Separate zinc from ibandronate by at least 60 minutes, and ideally take zinc later with food.
Adequate vitamin D supports safe and effective antiresorptive therapy by reducing hypocalcemia risk and supporting bone mineralization.
Recommendation: Correct vitamin D deficiency before or during therapy under clinician guidance.
Numbered references. Citations throughout the page link here.
Pivotal fracture trial supports vertebral fracture reduction and bone density improvement.
Guideline supports bisphosphonates for high-risk patients and adequate calcium and vitamin D intake.
Labeling describes monthly fasting dosing, 60-minute upright requirement, mineral separation, hypocalcemia correction, renal limits, and esophageal warnings.
This page is educational. Do not start, stop, or change a supplement or medication based on it without checking with a qualified healthcare professional.
Use this with your stack
Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.
NutriStack is an informational and organizational tool, not a medical service, and not a substitute for professional advice. Always consult a qualified healthcare professional before starting, stopping, or changing any supplement or medication.